Sequence: RRRRRRRRRRRRRRR-NH2
| Experiment Id | EXP001740 |
|---|---|
| Paper | Polyarginine-Mediated siRNA Delivery: A Mechanistic Study of Intracellular Trafficking of PCL-R15/si |
| Peptide | R15 (polyarginine 15-mer) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 100 nM for most comparisons (uptake negligible); 400 nM required to observe uptake per flow cytometry. |
| Mixing Ratio | Various N/P ratios tested; uptake negligible at 100 nM siRNA (uptake only observed at unusually high siRNA 400 nM). |
| Formulation Format | R15/siRNA electrostatic complexes (non-micellar; weak condensation) |
| Formulation Components | R15 peptide solution mixed with siRNA in equal volume in 5% glucose; vortex; stand 10 min. |
| Size Nm | 15.00 |
| Zeta Mv | 15.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa (human cervical cancer) |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro uptake comparison |
| Output Value | Failed to achieve significant cellular uptake at standard siRNA dose (100 nM); correspondingly poor delivery efficiency compared with PCL-R15. |
| Output Units | |
| Output Notes | HeLa uptake by flow cytometry after 4 h in Opti-MEM (heparin washes used to remove surface-bound siRNA). |
| Toxicity Notes | At 100 nM, viability favorable; lower cytotoxicity than PCL-R15 at high siRNA doses. |
| Curation Notes |